TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05619575

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CP1170 sound processor
Description: The CP 1170 sound processor will be used to determine the hearing performance with the new implementation of ForwardFocus in SCAN 2 (SCAN 2 FF), as assessed by speech perception in noise.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CP1150 Sound processor
Description: Active comparator off the ear sound processor.
Study: NCT05397145

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative analgesia management
Description: Intravenous 0.5 mg/kg tramodol and 400 mg ibuprofen will be administered to all patients 30 minutes before the end of the surgical procedure. In the postoperative period, patients will be administered ibuprofen iv 400 mg 3x1. Postoperative patient evaluation will be performed by another pain nurse who is unaware of the procedure. Patients in all groups will be attached to IV PCA containing 10 mcg/ml fentanyl, 10 mcg bolus without infusion dose, 10 min lock time protocol. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative analgesia management
Description: Intravenous 0.5 mg/kg tramodol and 400 mg ibuprofen will be administered to all patients 30 minutes before the end of the surgical procedure. In the postoperative period, patients will be administered ibuprofen iv 400 mg 3x1. Postoperative patient evaluation will be performed by another pain nurse who is unaware of the procedure. Patients in all groups will be attached to IV PCA containing 10 mcg/ml fentanyl, 10 mcg bolus without infusion dose, 10 min lock time protocol. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic.
Study: NCT06444568

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Intervention
Description: The intervention includes the application and follow-up of different diet therapies to individuals (Ketogenic diet and MIND).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: The intervention includes the application and follow-up of different diet therapies to individuals (Ketogenic diet and MIND).
Study: NCT05014971

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-neurohub
Description: Interdisciplinary care delivered using telemedicine (zoom) technology which includes neurologist, physical, occupational and speech therapy, social worker and dietician.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tele-neurohub
Description: Interdisciplinary care delivered using telemedicine (zoom) technology which includes neurologist, physical, occupational and speech therapy, social worker and dietician.
Study: NCT05444569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SC.
Study: NCT05458128

Intervention type: DRUG
Group type: OTHER
Intervention: Pitolisant
Description: Pitolisant 4.45 mg tablets~Pitolisant 17.8 mg tablets
Study: NCT06234189

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Defocus Incorporated Multiple Segment Spectacle Lenses (DIMS)
Description: 30 minutes without DIMS and 30 minutes with DIMS
Study: NCT05259566

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: menthol ban in cigarettes only
Description: menthol ban in cigarettes only, menthol available in e-cigarette
Study: NCT05444569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SC.
Study: NCT05259566

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: total menthol ban
Description: menthol ban in both cigarettes and e-cigarettes
Study: NCT05415761

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: iCanQuit
Description: iCanQuit is a smoking cessation smart phone application that uses acceptance and commitment therapy (ACT) approach, a cognitive behavioral treatment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: iCanQuit+Motiv8
Description: iCanQuit + Motiv8 is a integrated version of iCanQuit (Cognitive Behavioral Therapy smoking cessation therapy application) with Motiv8 (a contingency management program that rewards decreased smoking determined by measuring CO levels of participant)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Florida quit line
Description: An evidence-based, existing smoking cessation healthcare option recommended by the U.S. clinical practice that connects active smokers to trained quit coaches via referral by their providers.
Study: NCT06485479

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention ads
Description: The ads will be on topics to encourage quitting smoking, formatted as multi-color text with graphic elements. Trial investigators developed the ads and optimized them to be readable when delivered in an SMS text message.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention ads
Description: The ads will be on topics to encourage quitting smoking, formatted as multi-color text with graphic elements. Trial investigators developed the ads and optimized them to be readable when delivered in an SMS text message.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention ads
Description: The ads will be on topics to encourage quitting smoking, formatted as multi-color text with graphic elements. Trial investigators developed the ads and optimized them to be readable when delivered in an SMS text message.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control ads
Description: The ads will be on topics unrelated to quitting smoking, formatted as black text on a white field. Trial investigators developed the ads and optimized them to be readable when delivered in an SMS text message.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control ads
Description: The ads will be on topics unrelated to quitting smoking, formatted as black text on a white field. Trial investigators developed the ads and optimized them to be readable when delivered in an SMS text message.
Study: NCT05478265

Intervention type: DEVICE
Intervention: RS-4i Plus
Description: RS-4i Plus in an FDA-regulated prescription TENS medical device that outputs and INF signal and a NMES signal and Intersperse signal, which combines INF and NMES into a single treatment.

Intervention type: DEVICE
Intervention: RS-4i Plus
Description: RS-4i Plus in an FDA-regulated prescription TENS medical device that outputs and INF signal and a NMES signal and Intersperse signal, which combines INF and NMES into a single treatment.

Intervention type: DEVICE
Intervention: RS-4i Plus
Description: RS-4i Plus in an FDA-regulated prescription TENS medical device that outputs and INF signal and a NMES signal and Intersperse signal, which combines INF and NMES into a single treatment.

Intervention type: DEVICE
Intervention: RS-4i Plus
Description: RS-4i Plus in an FDA-regulated prescription TENS medical device that outputs and INF signal and a NMES signal and Intersperse signal, which combines INF and NMES into a single treatment.

Intervention type: DEVICE
Intervention: RS-4i Plus
Description: RS-4i Plus in an FDA-regulated prescription TENS medical device that outputs and INF signal and a NMES signal and Intersperse signal, which combines INF and NMES into a single treatment.

Intervention type: DEVICE
Intervention: RS-4i Plus
Description: RS-4i Plus in an FDA-regulated prescription TENS medical device that outputs and INF signal and a NMES signal and Intersperse signal, which combines INF and NMES into a single treatment.
Study: NCT05995210

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kinesio taping
Description: A corrective kinesio taping was applied to the patellofemoral joint for the knee. In addition, exercise therapy was taken.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orthosis
Description: They were asked to use a knee orthosis for a minimum of 6 hours a day. They also received exercise therapy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: An exercise program focused on the knee and hip muscles was given two days a week.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control
Description: An exercise program focused on the knee and hip muscles was given two days a week.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control
Description: An exercise program focused on the knee and hip muscles was given two days a week.
Study: NCT05904704

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oxygen Therapy
Description: Receive supplemental oxygen
Study: NCT05379803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furmonertinib
Description: furmonertinib 160 mg orally QD
Study: NCT05701423

Intervention type: DRUG
Intervention: Natalizumab
Description: Administered as specified in the treatment arm.
Study: NCT06033222

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ricinoleic Acid 750 mg
Description: 750 mg administered orally

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ricinoleic Acid 1500 mg
Description: 1500 mg administered orally

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ricinoleic Acid 3000 mg
Description: 3000 mg administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Contains no active ingredient.
Study: NCT06305650

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic
Description: Through oral probiotic intervention for 12 weeks, participants' BMI, body fat percentage, and waist-to-hip ratio will be measured at weeks 0, 6, and 12, and fecal samples will be collected at weeks 0 and 12 for gut microbiota analysis.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Through oral probiotic intervention for 12 weeks, participants' BMI, body fat percentage, and waist-to-hip ratio will be measured at weeks 0, 6, and 12, and fecal samples will be collected at weeks 0 and 12 for gut microbiota analysis.
Study: NCT05142787

Intervention type: DEVICE
Group type: OTHER
Intervention: Magseed Pro(R) and Sentimag(R) Gen3 by Endomagnetics
Description: placement of Magseed Pro \& localisation with Sentimag Gen3 in axillary lymph nodes and/or breast lesions

Intervention type: DEVICE
Group type: OTHER
Intervention: Magseed Pro(R) and Sentimag(R) Gen3 by Endomagnetics
Description: placement of Magseed Pro \& localisation with Sentimag Gen3 in axillary lymph nodes and/or breast lesions
Study: NCT05460754

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional-fed beef
Description: Participants in the conventional-fed treatment of the study will consume a conventional-fed steak meal for breakfast one morning.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional-fed beef
Description: Participants in the conventional-fed treatment of the study will consume a conventional-fed steak meal for breakfast one morning.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Organic grass-fed beef
Description: Participants in the organic grass-fed treatment of the study will consume a organic grass-fed steak meal for breakfast one morning.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Organic grass-fed beef
Description: Participants in the organic grass-fed treatment of the study will consume a organic grass-fed steak meal for breakfast one morning.
Study: NCT06275685

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SeizureWise algorithm
Description: An investigational algorithm which enables forecasting of future seizure probabilities based on the pattern and frequency of previous generalized tonic-clonic seizure (GTCS) events, as well as changes in physiological and behavioral variables

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multi-day Visualizations
Description: Multi-day visualizations of sensor derived data

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-day Visualizations
Description: Multi-day visualizations of sensor derived data
Study: NCT05093270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-23339
Description: Administered orally as a tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-23339
Description: Administered orally as a tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-23339
Description: Administered orally as a tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-23339
Description: Administered orally as a tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally as a tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally as a tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally as a tablet
Study: NCT06047834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care with Lofexidine
Description: Participants will be randomized 3:1 to treatment with standard of care with or without lofexidine. Subjects randomized to standard of care with lofexidine will be sequentially assigned to 1 of 3 dose levels: Dose 1 (32 μg/kg/day, administered as 4 μg/kg/day q3h), Dose 2 (20 μg/kg/day, administered as 5 μg/kg/day q6h), or Dose 3 (16 μg/kg/day to 24 μg/kg/day administered q6h, with the final daily dose level to be decided based on data collected in participants receiving Dose 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care with Lofexidine
Description: Participants will be randomized 3:1 to treatment with standard of care with or without lofexidine. Subjects randomized to standard of care with lofexidine will be sequentially assigned to 1 of 3 dose levels: Dose 1 (32 μg/kg/day, administered as 4 μg/kg/day q3h), Dose 2 (20 μg/kg/day, administered as 5 μg/kg/day q6h), or Dose 3 (16 μg/kg/day to 24 μg/kg/day administered q6h, with the final daily dose level to be decided based on data collected in participants receiving Dose 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care with Lofexidine
Description: Participants will be randomized 3:1 to treatment with standard of care with or without lofexidine. Subjects randomized to standard of care with lofexidine will be sequentially assigned to 1 of 3 dose levels: Dose 1 (32 μg/kg/day, administered as 4 μg/kg/day q3h), Dose 2 (20 μg/kg/day, administered as 5 μg/kg/day q6h), or Dose 3 (16 μg/kg/day to 24 μg/kg/day administered q6h, with the final daily dose level to be decided based on data collected in participants receiving Dose 2).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care without Lofexidine
Description: Participants will be randomized 3:1 to treatment with standard of care with or without lofexidine. Subjects randomized to standard of care without lofexidine wilt receive non-pharmacologic measures and morphine when indicated.
Study: NCT06058299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBAJ-876
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBAJ-876
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBAJ-876
Description: tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pretomanid
Description: 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pretomanid
Description: 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pretomanid
Description: 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pretomanid
Description: 200 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid
Description: 600 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: 600 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: 600 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: 600 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bedaquiline
Description: 200 mg for 8 weeks followed by 100 mg for 18 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HRZE
Description: Isoniazid (H) + rifampicin (R) + pyrazinamide (Z) plus ethambutol (E) fixed dose combination tablets dosed by weight

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HR
Description: Isoniazid (H) + rifampicin (R) fixed dose combination tablets dosed by weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR
Description: Isoniazid (H) + rifampicin (R) fixed dose combination tablets dosed by weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR
Description: Isoniazid (H) + rifampicin (R) fixed dose combination tablets dosed by weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR
Description: Isoniazid (H) + rifampicin (R) fixed dose combination tablets dosed by weight
Study: NCT04720183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Description: On Day 1, Day 5 and Day 9, a single oral dose of sulfasalazine tablets in fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3970
Description: On Day 5 and Day 9, a single dose of GLPG3970 oral solution in fasted state.
Study: NCT06466746

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Raising the Pulse faba bean-enriched bread
Description: 100 g of white bread produced using 40% faba bean enriched flour and 60% wheat flour will be provided in the breakfast meal with stork margarine, chocolate spread, a glass of orange juice and a glass of water containing the iron-57 stable isotope. An ad-libitum lunch consisting of pasta and a tomato sauce will be provide 6 hours after the breakfast.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional White Bread
Description: 100 g of white bread produced using 100% wheat flour will be provided in the breakfast meal with stork margarine, chocolate spread, a glass of orange juice and a glass of water containing the iron-57 stable isotope. An ad-libitum lunch consisting of pasta and a tomato sauce will be provide 6 hours after the breakfast.
Study: NCT06191458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: Primaquine 0.5 mg/kg (Government Pharmaceutical Organization, Thailand) will be given once daily with food for 14 days. This is the dose recommended by the World Health Organization for radical cure of P. vivax in tropical regions. Doses will be directly supervised (DOT).
Study: NCT05148156

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Urolift
Description: Study intervention involves a one-time administration of Urolift in out-patient setting prior to Stereotactic body radiation therapy (SBRT).
Study: NCT04415944

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Second look laparoscopy reassessment surgery (SLLRS)
Description: Performed less than 12 weeks after intravenous chemotherapy cycles are completed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIPEC with Carboplatin
Description: Patient receives HIPEC with CBDCA 800 mg/m2 for 90 minutes.~Patients who exhibit the following will not receive the HIPEC procedure:~* Extraperitoneal disease noted at the time of the second look procedure~* Macroscopic intraperitoneal disease which is not resectable to R1~* Technical problems which prevent continuous, adequate flow to maintain intraperitoneal temperature to 41°C during perfusion~* Intraoperative complications such as cardiac or pulmonary instability precluding HIPEC~Participation will consist of completing surveys regarding their cancer and allowing researchers to use information from their medical records for research.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FACT-O Quality of Life Questionnaire
Description: Participants will be asked to do this three times (pre-study, 3 months and 6 months). Surveys will be given at follow up visits for surgery. They should take about 10-15 minutes to complete.
Study: NCT06071377

Intervention type: OTHER
Intervention: Biologic Specimen Collection
Description: Participants will have blood and urine collected annually at Baseline, Year 1 and Year 2.
Study: NCT05321134

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single port robotic colorectal surgical procedure
Description: After screening and counseling, study subjects who wish to participate will undergo the colorectal surgical procedure (determined based on routine standard clinical care) using the alternate Intuitive Da Vinci Single Port SP system rather than the currently used multiport system, (Intuitive Da Vinci Multiport Xi System).~Using standardized case report forms, the investigators will track clinical parameters and describe the safety \& quality event rate for SP platform transabdominal and transanal colorectal operations.
Study: NCT06091241

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pre-operative Erector Spinae Plane block prior to DIEP surgery
Description: After obtaining informed consent to participate in the study, patients will be randomized by a computer 50/50 to either the Erector Spinae Plane group or the Transversus Abdominus Plane group at the time of their surgical clinic visit prior to their scheduled surgery. Then on the morning of surgery, the Erector Spinae Plane group will receive a bilateral ultrasound-guided Erector Spinae Plane peripheral nerve block. During this intervention, 0.25% bupivacaine with dexamethasone will be injected below the fascia of the erector spinae muscle group.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pre-operative Transversus Abdominus Plane blocks prior to DIEP surgery
Description: On the morning of surgery, the patients in the TAPs group will receive a bilateral ultrasound-guided Transversus Abdominus plane peripheral nerve block. During this intervention, 0.25% bupivacaine with dexamethasone will be injected into the transversus abdominus plane above the transversus abdominus muscle.
Study: NCT06195748

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotaping
Description: According to the manufacturer, the controllable variables in KT application included degree of pre-stretch applied to the tape (75-100%), the location and treatment goals. The subject will be asked to lie supine, with the ankle of the dominant side in neutral position. A Y shaped KT strip will be applied from the heel to lateral and medial femoral condyles. A I shaped KT strip will be applied from medial malleolus to lateral malleolus, passing under the heel. Another I shaped KT strip will be applied from slightly above the medial malleolus to slightly above the lateral malleolus, crossing on the instep at the malleoli level.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo kinesiotaping
Description: The same tape will be used for the interventional application with 0 tension.